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INTRODUCTION 
Outcome surveillance is an essential tool to determine the effectiveness 
of the national effort to control Tuberculosis1. It provides an insight into the proportion 
of patients who complete treatment, experience complications, lose follow up or die. 
The main purpose of treatment outcome monitoring is to determine the outcome of 
potentially infectious cases and thus it provides information about the likely 
transmission of infection. 
The Revised National Tuberculosis Control Programme (RNTCP), 
adopting the DOTS strategy advocated by World Health Organization (WHO), was 
implemented in 1993 in the country and has been scaled up rapidly since mid 1998. 
Based on a stringent diagnostic algorithm and history of previous TB treatment, the 
diagnosed cases under RNTCP are classified as ‘New’ and ‘Re-treatment’ cases for 
allotting an appropriate drug regimen to them.  
 Retreatment cases i.e. those who give history of previous TB treatment 
of more than one month, are put on Category II regimen. This category comprises 
smear positive ‘Failures’, ‘Relapses’, ‘Treatment after Default (TAD)’ and ‘Others’. 
The question often posed by clinicians is regarding effectiveness of Cat II regimen for 
re-treatment cases, especially those with failures.  It has been suggested that they may 
be treated with a stronger regimen since such cases are likely to harbor drug resistant 
organisms 2-3. We conducted a retrospective study to evaluate the outcome of  category 
II retreatment cases in a DOTS programme in Chennai city to examine if these 
concerns had any basis. 
 
 
 
  
AIM OF THE STUDY 
   
To evaluate the present status of a cohort of retreatment cases started on Category II 
ATT in the year 2002 in three tuberculosis units of Chennai city and to evaluate the 
effectiveness of Category II. 
 
 
DESIGN OF THE STUDY: 
Descriptive study 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE: 
 
Mycobacteria have played an extremely important role in influencing 
society through out its history4. Tuberculosis (TB) is an infectious disease caused by 
Mycobacterium tuberculosis, and rarely by other organisms of the “tuberculosis 
complex”. Tuberculosis is most commonly transmitted by inhalation of infected droplet 
nuclei which are discharged in the air when a patient with untreated sputum positive TB 
coughs or sneezes. If the bacillus succeeds in infecting a person, only about 5%–10% of 
such infected persons (primary infection) develop active disease. In the remaining 90% 
to 95 % of infected persons, initial infection usually goes unnoticed. Tuberculin 
sensitivity appears within a few weeks of infection and initial lesions commonly heal 
leaving no residual changes except occasional pulmonary or tracheo-bronchial lymph 
node calcifications (primary complex). 
 Infection occurs almost exclusively through the respiratory route. The 
infection may then spread from the primary lung lesion to any part of the body via the 
blood stream, lymphatic and bronchial systems. Post primary TB (active TB disease) 
arises from endogenous reactivation of latent foci which remained dormant since the 
initial infection or exogenous re-infection. Post primary TB usually affects the lungs 
(more than 85%) but can involve any part of the body. Pulmonary TB which is sputum 
smear-positive is if untreated, TB leads to death within 2–3 years in at least half the 
patients. About 20 to 25% have natural healing and 25 to 30% remain positive and 
continue to spread the disease in the community.  
 
 
 
Microbiology of Mycobacterium tuberculosis: 
The main defining characteristic of the genus Mycobacterium is the 
property of “acid-fastness”: that is, the ability to withstand decolorization with an acid-
alcohol mixture after staining with such stains as Ziehl-Neelsen or auramine. In 
addition to their being acid-fast, the mycobacteria are primarily intracellular parasites, 
have slow rates of growth (except for the “rapid grower” category), obligate aerobes, 
and in normal hosts induce a  granulomatous response in tissue. 
 
Diagnosis Of Pulmonary Tuberculosis : 
Sputum positive pulmonary TB patients are the main source of infection. 
It is estimated that an untreated smear positive pulmonary TB patient infects 10-15 
persons annually. Therefore, it is very important to identify TB suspects and diagnose 
them early in order to effectively treat and make them non infectious. 
Methods available for diagnosis of pulmonary tuberculosis: 
¾ Sputum smear microscopy 
¾ Chest X-ray 
¾ Culture 
¾ Tuberculin test 
• Sputum smear microscopy:  
This is the primary tool for diagnosing TB as it is easy to perform at the 
peripheral laboratories. It is not expensive. It is specific with low inter and intra reader 
variation. It is simple and requires minimum training. It can be used for diagnosis, 
monitoring and defining cure. Therefore, this is the key diagnostic tool used for case 
detection in RNTCP. If good diagnostic practices are followed, it is expected that at 
least 50% of the new pulmonary TB patients diagnosed will be smear-positive. A smear 
is made, fixed and stained using the Ziehl-Neelsen staining technique. Sensitivity of 
detection of acid-fast organisms is increased by a fluorochrome staining procedure with 
auramine O, a fluorescent stain. This procedure requires use of a fluorescent 
microscope but is faster than acid-fast staining because the intensity of the fluorescent 
signal enables slides to be scanned at lower magnification.  
Microscopic examination of sputum is, as a rule, the only way by which 
the diagnosis of pulmonary TB can be confirmed. Whenever TB is suspected, at least 3 
specimens of sputum should be collected over 2 consecutive days and examined by 
microscopy.  
 
Guidelines for collecting sputum for smear microscopy: 
• First visit to the microscopy centre: When a TB suspect reports to the laboratory   a 
specimen is collected on the spot. She/he is given a sputum container with the three 
times with his/her mouth open, cough out deeply from the chest, open the container, 
spit out the sputum into it and close the container tightly. This specimen is called a spot 
specimen. The patient is then given a similarly marked empty sputum container to 
collect a specimen early next morning and bring it to the laboratory. This specimen is 
called an early morning specimen. 
• Second visit to the microscopy centre:  
The early morning specimen brought by the patient is received and a further spot 
specimen is collected. Thus there will be three samples: SPOT-EARLY MORNING-
SPOT. Obtaining a good sputum specimen is crucial for quality sputum microscopy. 
The following steps have to be observed to get good sputum specimen: 
 
 
 • Tasks performed before sputum collection: 
 Before a health worker collects a sputum specimen, the reasons for sputum  collection 
have to be explained to the patient. The Laboratory technician/ health worker must 
ensure that the patient’s full  address is entered in the laboratory form. 
• Tasks performed during sputum collection:  
A specimen collected under the proper guidance of a health worker is likely to yield 
more conclusive results than one produced by a patient without any guidance. Sputum 
should preferably be collected in open air or in a vacant room with open windows. The 
health worker or the laboratory technician should stand behind the patient. The health 
worker should also ensure that no-one stands in front of the patient. If a patient coughs 
out only saliva, he should be asked to try again to bring out sputum. Patient must be 
asked to rinse the mouth before bringing out the sputum samples. 
• Tasks performed after sputum collection:  
Sputum specimens should be examined on the same day. In cases where sputum needs 
to be transported to a DMC it must be examined within a week after collection. Storage 
of sputum samples should be in cool place/ refrigerator. A smear is made, fixed and 
stained using the Ziehl-Neelsen staining technique 
 
• Chest X-ray:  
X-ray as a diagnostic tool is sensitive but less specific with large inter 
and intra reader variations. No shadow is typical of TB, 10-15% culture-positive cases 
remain undiagnosed and 40% patients diagnosed as having TB by X-ray alone may not 
have active TB disease. It is supportive to microscopy. 
 
 
• Culture:  
Definitive determination of species and antimicrobial susceptibility 
testing require culture of the organism. Culture of Mycobacterium tuberculosis bacilli is 
very sensitive and specific but is expensive as it requires a specialized laboratory set-up 
and results are available only after several weeks. If available, culture of tubercle bacilli 
may be helpful, although in sputum-negative cases a clinical decision to treat for TB 
based on X-ray findings and lack of response to broad-spectrum antibiotics would be 
more practical and also ensure prompt treatment. Culture and sensitivity testing is 
valuable for diagnosis and management of drug resistant tuberculosis, besides 
epidemiological surveillance and planning. Culture of sputum usually involves 
digestion and decontamination of the specimen before inoculating media. This process 
enables more uniform plating of the specimen and decreases bacterial overgrowth. For 
specimens other than sputum, digestion and decontamination are not required.  
It is generally recommended that two different kinds of media be 
inoculated: usually an egg-based one, such as Lowenstein-Jensen, and an agar-based 
one, such as Middlebrook-Cohn 7H10. 
 Egg-based media are generally regarded as the reference standard 4and 
may result in a larger number of positive cultures, whereas agar-based media enable 
earlier detection of growth. The main disadvantage of this procedures is the slow of 
mycobacteria which necessitates a mean incubation of 4-6 weeks on these conventional 
media. 
Colonies of rapidly growing mycobacteria may be visible in 2 to 5 days, 
whereas colonies of the slower growing organisms appear in 2 to 6 weeks. Cultures 
showing no growth at 6 weeks are reported as negative, although they generally are 
kept for another 2 to 4 weeks before being discarded. Simply from observation of rates 
of growth and pigment production, many of the non tuberculous mycobacteria can be 
differentiated from M. tuberculosis. A positive test for niacin production in essence 
confirms the isolate to be M. tuberculosis. In many laboratories, especially those 
processing large numbers of specimens, DNA probes are used routinely to identify 
mycobacteria grown in culture, thus obviating the need for many of the biochemical 
tests. Speciation of the non-tuberculous mycobacteria is important for separating 
pathogenic from nonpathogenic organisms and to indicate the initial approach to 
therapy on the basis of known drug susceptibility patterns of the various species.  
 
Radiometric Culture Systems: 
 Radiometric culture systems incorporate 14C-labeled palmitic acid into 
a liquid culture medium. Growth of mycobacteria results in liberation of 14CO2 that can 
be measured by the detection device. The increased sensitivity of the system enables 
growth to be detected sooner, usually in 10 to 14 days4. As noted earlier, a positive 
NAP test or DNA probe testing confirms an isolate as being M. tuberculosis. Because 
identifying patients with tuberculosis early is desirable and because of concern with 
multidrug-resistant organisms, radiometric detection and sensitivity test systems should 
be used in hospitals in which large numbers of patients with tuberculosis are managed.  
 
 
 
Nucleic Acid Amplification (NAA) Tests:  
NAA tests include those that involve PCR amplification, transcription-
mediated amplification (TMA), strand-displacement amplification (SDA), ligase chain 
reaction (LCR), and Q Beta replicase amplification. Each of these approaches has 
strengths and weaknesses. In each test, either DNA or RNA is amplified to detectable 
levels. Currently, rapid amplification tests are licensed only for use with specimens in 
which AFB have been found. This limitation has been applied because the sensitivity of 
the tests for specimens that are smear-negative but culture-positive is not sufficiently 
high to exclude M. tuberculosis with a negative result of a rapid test.  
 
 Restriction Fragment Length Polymorphisms: 
 Analysis of insertion sequence patterns in genomic DNA of M. 
tuberculosis has been shown to be a useful tool for studying the epidemiology and 
transmission dynamics of tuberculosis. Restriction fragment length polymorphism 
(RFLP) analysis is based on the finding that tubercle bacilli possess repetitive DNA 
sequences. Of these sequences, IS6110 is the most widely used and is found in 2 to 25 
copies per individual isolate or strain. The technique involves extracting DNA from 
cultured M. tuberculosis,      digesting it with restriction endonucleases, separating the 
resulting fragments by gel electrophoresis, and then using Southern blot analysis with 
labeled components of these insertion sequences to create a unique, strain-specific 
DNA fingerprint. In outbreaks of tuberculosis among patients with acquired 
immunodeficiency      syndrome (AIDS) in hospitals or in residential care facilities, 
isolates from   multiple patients have shown precisely the same banding pattern, which 
indicates spread of infection within the facility. Although this technique requires 
considerable technical expertise, it can be used to track the spread of strains of M. 
tuberculosis through a population or to detect unsuspected sites and patterns of 
transmission, and thus it could  have a significant impact on public health interventions  
 
Drug Susceptibility Testing: 
 Determination of susceptibility to antimicrobial agents is of 
considerable clinical importance. Although several techniques are used for determining 
resistance, the proportion method is most commonly employed in the United States and 
Canada. This involves inoculating one or more dilutions of cultured mycobacteria on 
drug-free media and on media containing appropriate concentrations of anti 
mycobacterial agents. Resistance is generally considered to be present when the growth 
on the drug-containing medium is 1% or more of the control growth. The standard drug 
concentrations used for defining resistance to the first-line drugs are as follows: 
isoniazid, 0.2 g/mL; rifampin, 1.0 g/mL; ethambutol, 5.0 g/mL; and streptomycin, 2.0 
g/mL. Susceptibility testing for pyrazinamide can be done only in a radiometric system. 
Testing of the second-line drugs is generally performed only in reference laboratories. 
Rapid radiometric measurements are also used to determine drug susceptibility and can 
provide results much more quickly than from cultures on solid media. The results 
obtained by this      technique have been quite consistent with the results of standard 
test procedures. 
 
• Tuberculin test:  
Reactivity to tuberculoprotein is the hallmark of a cell-mediated immune 
response to M. tuberculosis. Stated differently, a  positive response  to an appropriate 
skin test  antigen is assumed to be diagnostic of tuberculous infection. In fact, the 
tuberculin skin test is the only means of detecting tuberculous infection in  persons who 
do not have clinical tuberculosis4; hence, it is important both in  diagnostic and 
epidemiologic evaluations. Tuberculin test may be useful as an additional tool for 
diagnosing paediatric TB, in whom a positive test is more likely to reflect recent 
infection with TB and indicates a much higher risk of developing disease.  
 Extent of the Tuberculosis Problem 
Nearly one-third of the global population, i.e. two billion people, are 
infected with Mycobacterium tuberculosis and are at risk of developing the disease. 
More than  eight million people develop active tuberculosis (TB) every year, and about 
two million die5 . More than 90% of global TB cases and deaths occur in the 
developing world, where 75% of cases are in the most economically productive age 
group (15-54 years). There, an adult with TB loses on average three to four months of 
work time. This results in the loss of 20-30% of annual household income and, if the 
patient dies of TB, an average of 15 years of lost income6. In addition to the devastating 
economic costs, TB imposes indirect negative consequences - children leave school 
because of their parents' tuberculosis, and women are abandoned by their families as a 
result of their disease. Coinfection with the human immunodeficiency virus (HIV) 
significantly increases the risk of developing TB . At the same time, multidrug 
resistance, which is caused by poorly managed TB treatment, is a growing problem of 
serious concern in many countries around the world . Tuberculosis (TB) remains a 
major public health problem in India. About 40% of the population in India is estimated 
to be infected with TB bacillus. Every year approximately 1.8 million people develop 
TB and nearly 400,000 die from it. The annual incidence of smear positive TB is 
estimated to be 75 per 100,000 population (based on Annual Risk of Tuberculous 
Infection (ARTI) study done for the four zones of the country from 2000 to 2003. India 
accounts for one fifth of global incidence of TB and tops the list of 22 high TB burden 
countries. TB kills more adults in India than any other infectious disease.  
In India, every day7: 
• more than 5000 develop TB disease 
• more than 1000 people die of TB (i.e. 1 death every 1.5 minutes) 
The greatest burden of tuberculosis incidence and mortality in India is in adults aged 15 
to 60 years, which include the most productive members of society. TB affects more 
men than women, but still kills more women than all causes of maternal mortality put 
together. 
Every year due to TB (as per estimates made in 1997):  
• More than 170 million work-days are lost 
• nearly 300,000 school children dropout from the schools 
• more than 100,000 women are rejected by their families 
The HIV epidemic has the potential to worsen the TB situation, 
increasing the number of  TB cases and accelerating the progression of TB infection to 
active disease. It is estimated that 50 to 60 % of HIV infected people will develop TB 
disease in their lifetime when compared to 10% of HIV negative persons infected with 
TB. Another challenge to TB control in India is multi-drug resistant TB (MDR-TB). 
Fortunately the data available to date shows that levels of MDR-TB remain relatively 
low, at around 3%, amongst new patients and 12% in re-treatment cases. However 
these relatively low percentage figures translate into large absolute number of MDR-
TB cases, who can transmit their drug resistant disease to others and require effective 
treatment. 
 
 
 
The problem of MDR –TB: 
The phenomenon of drug resistance was detected very soon after the 
introduction of Streptomycin for the treatment of Tuberculosis in 1947. Today, with the 
greatly expanded efforts to strengthen Tuberculosis prevention and control programmes 
worldwide, there is growing concern about the currently reported and potential future 
rates of drug-resistant Tuberculosis, and more importantly, the emergence of strains 
resistant to Isoniazid and Rifampicin, defined as multi-drug resistant TB, or “MDR-
TB”. Drug resistance develops either due to infection with a resistant strain, or as a 
result of inadequate treatment, such as when a patient is exposed to a single drug, or 
because of selective drug intake, use of inappropriate non-standardized treatment 
regimens, irregular drug supply, poor drug quality, or rarely, erratic absorption of the 
medications.  
The magnitude of the problem: 
The emergence of strains of Mycobacterium Tuberculosis that are 
resistant to antimicrobial agents is a world-wide problem. In 1997, the first global 
report on drug resistance, published by the World Health Organization (WHO) and the 
International Union Against Tuberculosis and Lung Diseases (IUATLD) Global Project 
on Anti-Tuberculosis Drug Resistance Surveillance, contained data from 35 countries. 
The 2nd and the 3rd reports, published in 2000 and 2004, provided data from 50 and 63 
countries respectively8,9. The latter reported, the median prevalence of resistance to at 
least one drug among new TB cases as 10.2% (range 0 – 57.1%), with specific drug 
resistance being 5.9% for Isoniazid and 6.3% for Streptomycin9.According to the said 
report, the median prevalence of MDR-TB amongst new cases worldwide was 
estimated to be 1.1% (range 0 – 14.2%). Higher rates of resistance were found amongst 
previously treated patients, with median prevalence of resistance to at least one drug 
and MDR-TB being 18.4% and 7.0% respectively9. 
In India, drug resistance patterns vary widely across different parts of 
the country. The data on drug resistance in ‘new’ cases has been variously estimated by 
different investigators10. The first nation wide survey conducted by Indian Council of 
Medical Research (ICMR) during the 1960s showed a resistance level of 8.2% to 
Isoniazid (H) alone, 5.8% to Streptomycin (S) alone, and 6.5% to both the drugs 
(SH)11. Data published by the Tuberculosis Research Centre (TRC), Chennai have 
shown a gradual rise in the prevalence of resistance in ‘new’ cases over the past four 
decades, 3% to 17% for Isoniazid and 3% to 13% for Streptomycin. Drug resistance to 
Rifampicin emerged during the 1990s and data from the recent studies conducted by 
TRC and NTI, have reported MDR-TB levels between 0.5% to 3% in new cases and  
12% amongst re-treatment cases11-13. A high prevalence of MDR-TB is mostly due to 
poor TB case management. Any intervention designed to treat and /or control MDR TB 
must place the highest priority on correcting such errors in TB management, in the 
public as well as the private sector, prior to incorporating treatment for MDR-TB cases 
into the programme. Under the operational conditions, it has been observed that less 
than 3% of new cases fail to the Category I treatment regimen and 6% fail amongst the 
retreatment patients treated with the RNTCP Category II regimen. It is being realized 
that, as DOTS programmes around the world become robust enough to manage the 
majority of patients who carry drug-sensitive strains, efforts should begin to provide 
better services for the minority of patients with MDR-TB14-15. 
 
 
 
Journey of tuberculosis control movement in India : 
Era of Pre-chemotherapy: 
Tuberculosis has been recognized as one of the most ancient diseases 
which finds a place in the works of Ancient Ayurvedic System practiced by Sushrutha, 
Charaka and others around 2500 BC. As we all know, 24th March 1882 is a landmark 
day, as on this day, Robert Koch announced the discovery of causative organism of TB. 
This brought to the forefront, a totally new era in the struggle against TB. Its relevance 
continues till date. Koch’s discovery inspired many facets of research in prevention, 
control and therapeutic aspects of the disease. Unfortunately, there was no 
breakthrough in the treatment of TB for a long time to come. The only available mode 
of treatment was isolation, providing good food and ventilation in a sanatorium. The 
development of anti-TB drugs was acquired and sporadic over a period of two decades 
starting from 1940s. Streptomycin and  Para-Amino Salicylic Acid (PAS) were first 
introduced in 40s followed by Thioacetazone and Isonicotinic Acid Hydrazide (INH) in 
50s. This gave a global impetus for treatment and control of TB. In 1951, these drugs 
were tried out on smaller scale in a limited number of patients in Indian doctors.  
 
The Bhore Committee report in 1946 had come out with an estimate that 
there were about 2.5 million patients requiring treatment in the country and only a few 
thousand beds were available which indicated a wide gap that had to be bridged. The 
committee recommended establishment of an organized domiciliary service by setting 
up of TB clinics in the districts and mobile TB clinics for rural areas. The NSS was 
conducted (1955 to 1958) was an eye opener, which revealed that the problem of TB 
was uniformly distributed, both in the urban and rural population of the country. On an 
average, the bacillary cases were 4/1000 and X-ray active cases 16/ 1000.The National 
TB Control Programme (NTCP) formulated in 1962 and implemented throughout the 
country with limited resources was to create a good infrastructure in most parts of our 
country. A large number of key personnel of District TB Centers were trained in 
carrying out NTCP activities. It was also engaged in monitoring the TB control 
programme and providing feedback from time to time both to the central and state 
authorities. 
 
Era of Conventional Chemotherapy (1961 -1986): 
An integrated NTP was pilot tested in Ananthpur district of Andhra 
Pradesh during 1961 and thereafter the programme was launched in a phased manner 
throughout the country. The programme was expanded in a phased manner to cover 364 
districts using R1 to R5 regimen and monitoring being taken up on a regional basis 
initially and thereafter NTI took up the monitoring work for the entire country. From 
the analysis of monitoring reports and the observations made in a number of studies, it 
stood out prominently that the compliance with anti-TB treatment for 12 to 18 months 
was a big problem under field conditions. Researchers had already demonstrated that 
the duration of treatment could be brought down to 6-8 months.  
 
Era of Short course chemotherapy (1986 -1993): 
At this juncture, the name that first strikes the mind is that of Dr. 
Wallace Fox who, through British Medical Research Council units in East Africa, 
India, Hongkong and Singapore, handed over the greatest gift to the world i.e., SCC. 
He is considered as the father of clinical trials for chemotherapy of TB. With the 
introduction of Rifampicin and Pyrazinamide in the developed countries in early 1960s, 
a new era started in the battle against TB. This has been a very important milestone in 
the fight against TB on a global scale which brought enormous hope of early TB 
control. This finding enabled to cut down the duration of treatment to 6 -8 months. In 
1983, Tuberculosis Research Centre, Madras, pilot tested SCC in 18 districts of the 
country to assess the feasibility of its implementation on a larger scale. Government of 
India (GOI) agreed to the policy of implementation of SCC in 1986. In spite of the 
introduction of SCC, monitoring report as well as findings of some studies continued to 
show a high rate of defaulters and the disturbing trend of low compliance in SCC 
districts. Following the global review of the programme WHO in 1993 declared TB as 
a global emergency. 
 
 Era of Directly Observed Treatment Short course: 
(DOTS) -1993 -2005 In 1992, GOI-WHO carried out an in-depth review 
of TB programme in India as a part of global review and observed glaring deficiencies. 
In 1992, the Government of India, together with the World Health Organization (WHO) 
and Swedish International Development Agency (SIDA), reviewed the national 
programme and concluded that it suffered from managerial weakness, inadequate 
funding, over-reliance on x-ray, non-standard treatment regimens, low rates of 
treatment completion, and lack of systematic information on treatment outcomes. As a 
result, a Revised National Tuberculosis Control Programme (RNTCP) was designed.  
 
 
 
 
RNTCP -  AN OUTLINE: 
The RNTCP strengthens the existing NTP infrastructure by creating a sub-district-level 
supervisory team (known as the TB Unit), consisting of a treatment supervisor (Senior 
Treatment Supervisor, STS) and a laboratory supervisor (Senior TB Laboratory 
Supervisor, STLS). These are new posts. In addition, a medical officer from the general 
health system serves as Medical Officer—TB Control at sub-district level who is 
specifically allocated TB control duties in addition to his other duties. These 3 
individuals constitute the management unit, which is responsible for overseeing 
operations in approximately a 5 lakh population including, on average, 5 designated 
microscopy centers. More importantly, intensive modular training, supervision, and 
cross-checking of the work of the laboratory technician should ensure that reliable 
results are obtained.  
 
DOTS – an overview: 
The DOTS strategy has the following five components: 
1 Sustained political commitment. 
2 Access to quality-assured sputum microscopy. 
3  Standardized short-course chemotherapy for all cases of TB under proper 
case management conditions, including direct observation of treatment. 
4 Uninterrupted supply of quality-assured drugs. 
5 Recording and reporting system enabling outcome assessment of all 
patients and assessment of overall programme performance. 
 
Directly Observed Treatment (DOT), in which a trained peripheral health worker or 
community volunteer watches as patients swallow all medicines, is fundamental to 
ensuring cure. DOT should be ensured for every dose in the intensive phase of 
treatment and at least the first dose of the week in the continuation phase. DOT is one 
of the five components of the DOTS strategy.  
Classification of tuberculosis cases 
It is important to classify cases of TB in order to determine the correct combination of 
drugs and duration of treatment. Classification of pulmonary cases should be based on 
at least 3 sputum smear examinations. Sputum should also be examined for cases of 
suspected extra-pulmonary TB if pulmonary symptoms are present. 
Pulmonary tuberculosis 
a. Smear-positive patient 
A patient with at least 2 initial sputum smear examinations (direct smear microscopy) 
positive for acid-fast bacilli (AFB); 
Or: A patient with one sputum examination positive for AFB and radiographic 
abnormalities consistent with active pulmonary TB as determined by the treating MO; 
Or: A patient with one sputum specimen positive for AFB and culture positive for   
M.tuberculosis. 
b. Smear-negative patient 
A patient having symptoms suggestive of TB with at least 3 sputum examinations 
negative for AFB, and radiographic abnormalities consistent with active pulmonary TB 
as determined by the treating MO, followed by a decision to treat the patient with a full 
course of anti-TB therapy; 
 
Or: A patient whose diagnosis is based on culture positive for M. tuberculosis but 
sputum smear examinations negative for AFB. 
Extra-pulmonary tuberculosis 
Extra-pulmonary tuberculosis (EPTB) is tuberculosis of organs other than the lungs, 
such as the pleura (pleurisy), lymph nodes, intestines, genito-urinary tract, skin, joints 
and bones, meninges of the brain, etc. 
Diagnosis should be based on one culture-positive specimen from an extra-pulmonary 
site, or histological or radiological, or strong clinical evidence consistent with active 
extra-pulmonary TB followed by the treating MO’s decision to treat with a full course 
of  anti-TB therapy. Pleurisy is classified as extra-pulmonary TB. A patient diagnosed 
with both sputum smear positive pulmonary TB and extra pulmonary TB should be 
classified as a case of pulmonary TB. 
 TREATMENT : 
The objectives of Tuberculosis treatment are: 
• To decrease mortality and morbidity by ensuring cure, minimizing relapses and 
preventing development of drug resistance 
• To decrease infections and break the chain of transmission of infection 
• To achieve the above whilst minimizing side effects due to drugs 
These objectives are achieved in RNTCP through intermittent (thrice weekly) treatment 
regimens given under direct observation for both pulmonary and extra-pulmonary 
tuberculosis patients. Treatment regimens for tuberculosis have emerged as a result of 
controlled clinical trials in India and other parts of the world. It has been proven that 
thrice-a-week (intermittent) treatment is as effective as daily treatment and produces 
lesser side effects.  
RNTCP provides standardized anti-TB treatment in three categories.  
Category of 
Treatment 
Type of patient Regimen 
Category I 
New sputum smear-positive 
Seriously ill new sputum negative 
Seriously ill new Extra-pulmonary 
2H3R3Z3E3+4H3R3 
Category II 
Sputum smear-positive relapse 
Sputum smear-positive failure 
Sputum smear-positive Treatment After 
default, Others 
2H3R3Z3E3S3+ 
1H3 R3Z3E3+5H3R3E3 
Category III 
 
New sputum negative not, seriously ill 
2H3R3Z3+4H3R3 
New Extra-pulmonary, not seriously ill 
 
 
 
Definition of types of cases: 
New 
A TB patient who has never had treatment for tuberculosis or has taken anti 
tuberculosis drugs for less than one month. 
Relapse 
A TB patient who was declared cured or treatment completed by a physician, but who 
reports back to the health service and is now found to be sputum smear-positive. 
 
 
Transferred in 
A TB patient who has been received for treatment in a Tuberculosis Unit, after starting 
treatment in another unit where s/he has been registered. 
Treatment after default 
A TB patient who received anti-tuberculosis treatment for one month or more from any 
source and returns to treatment after having defaulted, i.e., not taken anti-TB drugs 
consecutively for two months or more, and is found to be sputum smear-positive. 
Failure 
Any TB patient who is smear-positive at 5 months or more after starting treatment.  
Failure also includes a patient who was treated with Category III regimen but who 
becomes smear-positive during treatment. 
Chronic 
A TB patient who remains smear-positive after completing a re-treatment regimen. 
 
Others 
TB patients who do not fit into the above mentioned types. Reasons for putting a 
patient .In this type must be specified. 
 
Treatment outcome: 
The patient’s treatment outcome is identified by reviewing her/his 
Tuberculosis Treatment Card. The treatment outcome and the date the patient stopped 
treatment is written in the appropriate column in the Tuberculosis treatment card. The 
date on which the patient stopped treatment is the date of the last dose of drugs taken. 
The duplicate TB Treatment card and the used / partially used PWB of the patient 
should be immediately returned by the PHW to the PHI. The MO of the PHI should 
record the treatment outcome in the treatment card and sign it. The treatment card of 
the patients whose outcome has been declared and partially used PWBs, if any, should 
be handed over to the STS during his routine monthly visits.  
 
Tuberculosis Register is kept at the Tuberculosis Unit which is at sub-
district level and contains information on all TB patients registered in the area. The 
Tuberculosis Register is used to record the following information about the patient: 
Tuberculosis Number (TB No.); Date of registration; Name (in full), address, age/sex; 
Name of PHI; Date of starting treatment; Regimen/Category; Disease classification; 
Type of patient; Details of sputum examinations; Treatment outcome with date; 
Remarks; and Summary at the bottom of the page  
 
 Monitoring: 
The programme is monitored on a quarterly basis from reports which 
include the report on case finding, sputum conversion, treatment outcomes and 
programme management. The programme has also evolved an in-built monitoring 
system. The quarterly reports are analyzed using the list of indicators at all levels, from 
the PHI, TU level, district, state to the centre. Detailed feedback on the performance of 
the districts is sent to the districts by the state at the end of every quarter in order to 
support the districts to improve performance. CTD gives additional feedback and helps 
in building the capacity of the state to monitor and evaluate the programme in their 
respective states. Besides the routine monitoring of the quarterly performance reports, 
the programme undertakes specific measures to monitor the programme 
implementation in the districts. 
 
Achievements of RNTCP: 
Starting in October 1993, the RNTCP was implemented in a population 
of 2.35 million in 5 sites in different states .The programme was expanded to a 
population of 13.85 million in 1995 and 16 million in 1996.  In the past years RNTCP 
has been expanding rapidly as shown below: 
Year 1998 1999 2000 2001 2002 2003 2004 2005 
Population 
Covered 
cumulative, 
in millions 
18 130 287 450 530 775 947 1059 
 
¾ RNTCP is the largest and the fastest expanding programme in the world. 
Quality of services has been maintained during this rapid expansion. 
¾ Treatment success rates have tripled from 25% to 86%. TB death rates have 
been cut 7-fold from 29% to 4%.  
¾  Since its inception, the Programme has initiated over 4.4 million patients on 
treatment, thus saving nearly 8 lakh additional lives. 
¾  During the year 2004, sputum positive case detection rate of 72% was achieved 
against the target of at least 70% and treatment success rate of 86% was 
achieved surpassing the global target of at least 85%..  
¾ The one-billion population coverage mark was reached in March 200517; 
Revised National Tuberculosis Control Programme (RNTCP) achieved a 
landmark in 2005 when DOTS services were extended to all the districts of the 
country16. 
Challenges:  
 The challenges ahead include the following: maintaining quality of 
services, addressing multi-drug resistance, dealing effectively with TB/HIV co-
infection, wider involvement of other sectors, contributing to the strengthening of 
health systems, empowering communities, and promoting research.  These components 
are central to the new WHO Global Stop TB Strategy. The union government admitted 
that the number of HIV positive persons has peaked to cross the five million mark. A 
few other risk factors for TB such as poverty, spatial proximity to infectious patient due 
to overcrowding in urban household settings, homelessness, smoking and co-
morbidities like diabetes, silicosis, and malnutrition besides HIV/AIDS continue to 
exist unabated. The inter-play of multiple factors both on plus and negative side calls 
for monitoring of the situation on a continual basis. This will help us to keep our 
responses timely and adequate. This brings in to focus the need to prioritize 
surveillance for TB to supplement RNTCP activities. National TB institutes at Chennai 
and Bangalore are already making inroads in operational research. It is imperative that 
a nationwide surveillance is implemented at the earliest so that early gains made by 
RNTCP can be carried forward. 
In the context of control of TB, as for other diseases, it is important to evaluate the 
current burden of disease, to know how this has been changing over time, and to 
determine how it is likely to change in the future. It is also imperative to determine the 
effectiveness of ongoing TB control activities. An intelligent use of the available data 
and good understanding of the epidemiology helps design control strategies that are 
likely to be effective and are cost-effective too 
 
 
The Revised National Tuberculosis Control Programme (RNTCP), 
adopting the DOTS strategy advocated by World Health Organization (WHO), was 
implemented in 1993 in the country and has been scaled up rapidly since mid 1998. 
Based on a stringent diagnostic algorithm and history of previous TB treatment, the 
diagnosed cases under RNTCP are classified as ‘New’ and ‘Re-treatment’ cases for 
allotting an appropriate drug regimen to them. Retreatment cases i.e. those who give 
history of previous TB treatment of more than one month, are put on Category II (Cat 
II) regimen. This category comprises smear positive ‘Failures’, ‘Relapses’, ‘Treatment 
after Default (TAD)’ and ‘Others’. 
 
Recently, concerns have been expressed that treatment with Category II 
regimen may not be effective since a single drug has been added to the failed regimen. 
It has been suggested that they may be treated with a stronger regimen since such cases 
are likely to harbor drug resistant organisms. Quy et al.2 provide evidence that the 
principle “do not add a single drug to a failing regimen” should be followed rigorously 
if one wants to ensure proper cure of cases who fail treatment with first-line drugs.  
 
 A prospective study was undertaken by Sophia Vijay and V.H. 
Balasangameshwara, et al 18 in the RNTCP centres of Bangalore Mahanagara Palike 
(BMP) to study the treatment outcome of patients treated with Category II regimen. A 
cohort of 226 smear and culture positive re-treatment cases, initiated on Category II 
regimen under DOTS, was followed up prospectively from April 1999 to September 
2001. The cohort was interviewed at the initiation and end of treatment using a pre-
tested semi-structured questionnaire to elicit details regarding past and present 
treatment. More than half of the study group (60%) was initially susceptible to all the 
regimen drugs. MDR –TB among the cohort was 12.8%. ‘Treatment after default’ cases 
constituted bulk of the cohort (65.5%) and ‘defaults’ among them were high. The 
overall favorable re-treatment outcome in the cohort was only 39.8% as a result of a 
high proportion of ‘defaults’ (43.8%). However, favorable outcome among those 
completing the prescribed duration of treatment was 75%, irrespective of pre-treatment 
drug susceptibility status. In addition, emergence of drug resistance, especially to 
Rifampicin, was negligible (1.8%) during current treatment despite the high default rate 
suggesting effectiveness of Category II regimen. Despite previous TB treatment, 60% 
of the study cohort was pre-treatment susceptible to all the four drugs despite the 
prevailing concept that a  majority of the re-treatment cases have acquired drug 
resistance and may not respond to Category II regimen. Treatment adherence is crucial 
for the success of chemotherapy. Deaths being negligible, the overall high proportion of 
‘default’ in the study group had considerably affected the expected favorable outcome, 
which represents failure to keep patients on DOTS, rather than ineffectiveness of 
Category II regimen. The high default rate observed in the study area compared to the 
15% average default rate among all patients on Cat II regimen from 1993 to 1998 in 
India is notable. 
One of the important findings of this study is the emergence of 
Treatment After Defaults (TAD) as potential defaulters. TADs constituted a majority of 
the study group and were pre-treatment drug sensitive, and hence amenable to 
treatment, but continued to default during present treatment. The argument against 
Category II regimen for re-treatment cases by many physicians is the fear of adding a 
single drug to a failing regimen, causing emergence of further drug resistance, 
particularly MDR. Majority of the pre-treatment susceptible group in the present study, 
however, either became negative or remained susceptible. The overall emergence of 
resistance to Rifampicin during treatment under direct observation was negligible 
(1.8%), despite a high default rate. This further supports the robustness of the category 
II regimen given under direct observation, in preventing the emergence of drug 
resistance during treatment. 
 
In another study by T. Santha, P.G. Gopi, R. Rajeswari and N. 
Selvakumar et al19 to find out whether it is worth treating category I failure patients 
with Category II regimen .Sputum samples were collected from new sputum smear-
positive patients declared ‘failure’ after treatment with Category I regimen under 
tuberculosis control programme using DOTS strategy from a rural area of Tamil Nadu. 
Of 1463 patients started on Category I regimen between May1999 and December 2002, 
74 cases were declared as ‘failures’ (smear positive at 5/6 months of treatment). 
Sputum samples were collected from 60 (81%) of 74 ‘failures’ and 27% (16 of 60) of 
them were culture-negative for M tuberculosis and 17% (10 of 60) had organisms 
resistant to Isoniazid and Rifampicin (MDR TB). Their  finding that nearly 80% of the 
‘failures’ (as declared in the programme, based on smear results), have organisms 
susceptible to R, justifies the use of the currently recommended category II regimen  
for failures of category I treatment. They concluded that close monitoring of these 
patients will be required to identify failures early and if necessary, change of treatment 
can be considered for those patients who do not show any response to treatment with 
Cat II regimen at 3-months.  
 
 
 
Quy et al2 describes  that it is the time to abandon the standard 
retreatment regimen with first-line drugs for failures of standard treatment . The study  
provides evidence that the principle “do not add a single drug to a failing regimen” 
should be followed rigorously if one wants to ensure proper cure of cases who fail 
treatment with first-line drugs. This  study from Vietnam had reported 80% of Category 
I failure cases to have MDR TB. On the treatment regimen (2SRHZ/6HE), the findings 
of Quy et al. call for strategies to reduce amplification and, perhaps, failure among 
patients with primary drug resistance. As most resource-limited high-burden countries 
do not have the means to test every new case of tuberculosis for drug susceptibility at 
enrolment, innovation is needed to address the issue. 
Regarding the retreatment regimen (2SHRZE/ 1HRZE/5H3R3E3), these results  
suggest its abandonment so that failure cases of the first-line treatment regimen can 
benefit from a stronger regimen. The principle raised previously, that such a   
retreatment regimen can still achieve bacteriological cure because of the possibility of 
susceptibility to R and E in this setting, is no longer valid for failure cases,20 as this 
study clearly shows that in such cases MDR-TB is the predominant pattern where 
tuberculosis control programmes are of good quality and no other reason for failure 
exists. Thus, if countries adopt culture and susceptibility testing for sputum smear-
positive patients at the end of the intensive phase with 2SRHZ/6HE or 2RHZE/6RH, 
and MDR is confirmed, a retreatment regimen including second-line drugs should be 
mandatory. Patients with resistance to two or more first line drugs, other than MDR, 
may also be candidates for the addition of second-line drugs.21 Standard retreatment 
regimens under programme conditions or tailored regimens through centers of 
excellence   could be used,      depending  on     feasibility issues   and           available  
Resources.22-23 If culture and susceptibility testing are not available, standard 
retreatment regimens with secondline drugs can be attempted for use as soon as failure 
is declared, by means of smear microscopy after 5 months of treatment, as in Peru. 
Some may perceive these suggestions as too radical, but international 
policy is an evolving process that needs to be adapted to emerging new evidence.Others 
may claim costs as the impeding issue. However, in the last few years funding for 
tuberculosis has increased substantially (although much more is needed), and what 
could not be done 20 years ago may be possible now.24 The DOTS-Plus initiative of the 
WHO and partners is bringing hope, as concessionally lowpriced, 
second-line drugs have been approved for use in 14 sites by the WHO-housed Green 
Light Committee under the DOTS framework following strict technical guidelines.25 
Given the encouraging results, the WHO has recently revised its policy for failure cases 
and recommended retreatment including second-line drugs in the presence of MDR-
TB. Cure rates of failure cases treated with the retreatment regimen of first-line drugs 
alone in Vietnam and Peru are, respectively, 46% and 47%.2,26.The success rate in 
Morocco is only 57%. Such figures for countries with excellent tuberculosis control are 
simply unacceptable27. 
 
Re-treatment cases have a higher likelihood of drug resistance which 
may have been acquired through inadequate prior chemotherapy26. They are also more 
likely than new patients to harbour and excrete bacilli resistant to at least to isoniazid. 
The re-treatment regimen consists of 5 drugs in the initial phase and 3 drugs in the 
continuation phase . Three of the drugs RHE – are given through out the treatment .  
This standardized regimen can cure patients excreting bacilli still fully sensitive to the 
drugs and those excreting bacilli resistant to isoniazid and/ or streptomycin. Under 
proper case management conditions , MDR-TB cases are those most at risk of failure in 
the re-treatment regimen26. 
The first alternative for the national tuberculosis programmes with 
limited resources is to use a Category II regimen, as for other re-treatment cases. 
However, failures to regimen I have a higher probability of being multi-drug resistant, 
particularly if the whole treatment was directly observed and included rifampicin in the 
continuation phase. Regimen II has poor results in MDR-TB cases (less than 50% cure 
rate). An option for countries implementing      regimen IV with reserve drugs is to use 
this regimen in failures to regimen I with proven MDR-TB. This requires sufficient 
resources (clinical, laboratory and drugs), availability of culture and susceptibility 
testing, and capacity to maintain patients on treatment for long periods. Before regimen 
IV is routinely for those who fail Category I regimen, national tuberculosis programme 
should first strengthen the management of Category I patients, including putting all 
patients on directly observed treatment26. Only after further strengthening case 
management practices should the programme move to provide reserve anti tuberculous 
drugs. 
Failures to Category I treatment regimen may not always have MDR-
TB26, particularly if the entire treatment was not directly observed or if the continuation 
phase did not include rifampicin. National TB programmes may therefore provide the 
standard Category II re-treatment regimen until the results of susceptibility testing are 
known. This will enable a more efficient use of available resources. Culture and 
susceptibility should be performed as soon as patients fail treatment.  
 
 MDR-TB is one of the main causes of failure to a Category I treatment 
regimen in patients who are treated under strict observation. Studies conducted in Peru 
and Viet Nam, two countries in which DOTS has been implemented successfully, have 
shown that Category I treatment failures commonly have MDR-TB. 
 
In programmes that have applied the strategy for several years  chronic 
cases represent less than 2% of the total smear-positive PTB cases. Careful cohort 
analysis of these subgroups of re-treatment cases is essential to assess the magnitude of 
chronic cases and, whenever possible, the proportion of MDR-TB among chronic cases 
It would be irrational for any country to divert resources to regimens with reserve drugs 
if a large proportion of new infectious cases remain untreated or ineffectively treated 
and short-course chemotherapy with drugs has not reached its full therapeutic 
potential26. 
 
A programme-based study from Malawi by Harries AD, Nyierenda 
TE, Kemp JR, et al 28 had reported that none of the failures to first line treatment with 
6HE in the continuation phase following an intensive phase of either 2SHRZ or 
2HRZE3 had MDR TB. Of the 90 patients who failed their first course of treatment, 48 
(53%) were cured by the programme and one patient (1%) completed treatment without 
a smear examination at 8 months. Altogether 17 (19%) patients died, four (4%) refused 
treatment, six (7%) had a treatment outcome other than cured, treatment completed or 
died, and for 14 (16%) there was no information available. Of the 90 patients who 
failed treatment, 31 (34%) had sputum specimens sent either to the Central Research 
Laboratory. Of these, 11 specimens grew organisms resembling M. tuberculosis. Of the 
remainder, two specimens grew organisms that were not M. tuberculosis, 15 were 
culture-negative and three were contaminated. Of the 11 cultures with M. tuberculosis, 
eight showed full sensitivity to all drugs tested, while three showed mono-resistance to 
isoniazid and full sensitivity to the other drugs. This study confirms that the Malawi 
NTP policy of  offering a standard WHO retreatment regimen to failure cases is entirely 
appropriate.For failure patients started on a retreatment regimen the cure rate was 75%. 
This study was country-wide, assessed the management of failed cases 2 
to 3 years previously, and is therefore probably representative of the current 
management practices of treatment failures in Malawi. This study was country-wide, 
assessed the management of failed cases 2 to 3 years previously, and is therefore 
probably representative of the current management  practices of treatment failures in 
Malawi. 
 
Tuberculosis research centre Chennai in a controlled clinical trial of 
using standardized short-course regimens for treating newly  diagnosed sputum smear 
positive (NSS) patients, 81% of 320 patients with H resistance, had favourable 
treatment outcome and 13% had bacteriological relapse, respectively, during a 24-
month period of follow up. Thus, 18 patients with resistance to H at  the time of failure 
also are likely to respond to treatment with Cat II regimen. Another 27% were negative 
by culture and there is no cause for concern in treating these patients with Category II 
regimen.  
 
 
According to T. Santha  et al 29 the patients who have relapsed can 
achieve more than 80–90% cure if treated for 8–9 months with five drugs, including 
rifampicin, during the intensive phase and three drugs in the continuation phase, since 
more than 80% of the relapses occur with drug-susceptible organisms 30. 
 In patients who had incomplete prior treatment, response will depend upon 
the drugs and dosages given during the prior treatment and the duration of treatment 
since these factors influence subsequent drug susceptibility 31. In well performing 
programmes, 70–80% of these patients are cured 32. Smear-positive patients who have 
failed a directly observed short-course treatment or re-treatment regimen have a low 
probability of cure with regimens that include only first-line drugs, as the probability of 
resistance to several of the drugs is high. Treatment of these patients with reserve drugs 
for a long period (18–24 months) can achieve relapse-free cure in two-thirds of them at 
best .Most patients who default or relapse can be cured with a retreatment regimen. 
Thus, there is little potential for new drugs to increase cure rates. However, new drugs 
could promote tuberculosis control by reducing the duration or frequency of treatment. 
The most important cause of tuberculosis treatment failure among detected patients is 
non-completion of treatment, or default. The most important cause of tuberculosis 
programme failure is a low rate of treatment completion, as defaulting patients continue 
to transmit tuberculosis in the community, sometimes with acquired drug resistance. 
Treatment success rates of at least 70–85% are necessary to ensure a substantial 
reduction in the incidence of tuberculosis. Systematic cohort analysis frequently reveals 
that less than half of patients who start treatment actually complete it. Treatment 
regimens capable of curing almost every tuberculosis patient have been available for 
more than 40 years, yet a large proportion of the patients detected have not been 
successfully treated.  In a 1964 report of a community-based tuberculosis treatment 
programme in southern India using a regimen of isoniazid plus paminosalicylic acid 
(PAS), only 64% of 123 patients were culture-negative after 12 months although the 
regimen was capable of a 90% cure rate 31. The low level of success was attributed to 
failure of the health delivery services to maintain patient adherence to treatment. By the 
end of the 12-month period 27% of patients had refused treatment, 10% had died or 
moved, and fewer than half of the remainder had collected at least 80% of their 
medication. 
 
In a a longitudinal survey and analytical studies, it was found that 
relapse still accounted for about 15–20% of the annual incidence of newly registered 
infectious cases.Controlled clinical trials in which patients were followed up regularly 
for 2 years or more have shown that the frequency of relapse is around 3–7% with 
standardized short-course chemotherapy. Similar results were obtained with either a 6-
month regimen using rifampicin throughout the treatment period or 8 months if 
rifampicin was given only in the initial intensive phase of treatment. Approximately 
80% of the relapses occur within the first 6 months of stopping treatment. More than 
80% of relapses occur with organisms susceptible to the tuberculosis drugs used earlier 
33 and hence their re-treatment does not pose a problem. It was also found that the 
individual risk of relapse among persons with a history of bacteriologically confirmed 
tuberculosis varied substantially and was determined mainly by three factors: —
whether treatment had been received or not (in case treatment was not given, the patient 
would be considered to have recurrent tuberculosis, not to have relapsed); —whether or 
not the regimen given was adequate and regularly taken; and —the time that had 
elapsed since smear/culture conversion to negative was achieved. The highest relapse 
rate is found in patients who have never received any treatment 
(about 5% per annum) and the next highest rate (about 2%) in patients with prior 
inadequate treatment 34. After 3–5 years, the risk in both groups diminishes 
appreciably, to about 1% 34 . In patients who have been adequately treated, the risk of 
relapse is too small to justify prolonged follow-up 35. Thus, routine follow-up 
examinations are generally unnecessary. This conclusion was reached by the Centers 
for Disease Control of the Public Health Service in the USA 36, as well as by 
investigators who followed up patients treated in Scotland . The former stated 36 
“Tuberculosis patients who complete adequate chemotherapy should be considered 
cured. They have no need for routine lifetime periodic recall for X-ray examination. 
Indeed, perpetuating life-time follow-up of such treated patients diverts clinic personnel 
and resources from the crucial task of providing services for those who really need 
them.” However, ex-patients should be strongly advised to come for examination 
without delay if they develop symptoms suggestive of tuberculosis 35. General 
practitioners and physicians who are likely to encounter patients with a history of 
previous tuberculosis should be informed about the possibility of relapse and the need 
to promptly evaluate recurrent respiratory symptoms (such as prolonged cough). 
However, it should also be understood that, among symptomatic ex-patients, cough is 
more the result of irreversible, bacteriologically quiescent lung damage than of 
recurrence of active tuberculosis disease . 
 Failure to begin a standardized retreatment regimen in Tuberculosis patients 
unresponsive to initial therapy may be the most important threat to the worldwide 
management of Tuberculosis, according to a U.S. Centers for Disease Control and 
Prevention (CDC) report. CDC December 14th, 1998   The CDC report further found 
that inappropriate therapeutic additions or subtractions during treatment for 
Tuberculosis are also a significant threat.  
The level of drug resistance in the community is closely related to the efficiency         
of treatment1. Multi-drug resistant (MDR) Tuberculosis is, to a large extent, the result 
of the past ineffective Tuberculosis programmes and practices. There is now an 
increased awareness about drug resistance posing as a major threat to patients and a 
challenge to Tuberculosis control programmes. 
 
Observations show that a previous treatment outcome and current 
clinical and epidemiologic histories can be used to predict the development of MDR-
TB and adverse outcomes in patients undergoing retreatment for TB. Such information 
may be useful for identifying appropriate patient candidates for programs such as 
directly observed therapy. 37 
 
Treatment outcome results serves as a tool to control the quality of TB 
treatment provided by the health care system. The aims of this study were to evaluate 
the treatment outcome for new culture positive pulmonary TB cases registered in 
Norway during the period 1996–2002, and to identify factors associated with non-
successful treatment.In that study1, the total treatment success rate for new culture 
positive pulmonary TB for the period 1996–2002 was 83%. This is close to the WHO 
target of success rate of 85% of all smear positive cases. That study shows a default 
rate of 3%. Default can constitute a major public health problem. Although incomplete 
treatment can prevent patients from dying from TB, the patients may remain infectious 
and even develop MDR-TB. It is therefore worrying that several patients in their study 
who defaulted treatment had isolated INH resistant strains or MDR-TB prior to 
treatment. Language problems, lack of understanding of the patients' cultural 
background, lack of communication between primary health care and hospitals, 
frequent change of address and stigma related to TB might be some of the reasons for 
defaulting. DOT was used on an individual basis during the study period, especially 
when an increased risk of non-adherence was suspected, but it became mandatory in 
Norway from 2003 according to the new TB regulations . Adoption of this strategy will 
hopefully improve treatment adherence further. 
Sophia Vijay, VH Balasangameswara et al38 conducted a study to 
address the problem of default among cohorts of new and re-treatment   cases   treated 
under       DOTS in a   metropolitan city.  The non-availability of more than one third of 
defaulters at final interview was mainly due to temporary migration  to their native 
villages. This is a common occurrence in the urban environment , where people move 
from rural to urban areas for seeking employment. Failure to thrive in cities after an 
illness may compel them to return to their native habitat. This problem could be 
circumvented   successfully  through an efficient  referral/transfer system as 
recommended in RNTCP.Provision of this facility should be made known to patients 
repeatedly during treatment. 
Santha T et al 39discussed about the progress of treatment and how it 
can be monitored? There are three approaches to monitor the progress of patients 
during treatment namely bacteriological, clinical, and radiographic assessment.  
Bacteriological assessment: 
 Bacteriological assessment can be done by smear and culture. Although culture is more 
specific, it is time-consuming and costly and there is a delay in getting the results. 
Moreover, appropriate facilities are not universally available. Hence the management of 
patients is generally based on smear microscopy. 
With short-course treatment, the organisms are killed rapidly, but dead bacilli may be 
excreted for some time, with the result that smears may be positive in some patients 
even when they are responding well to treatment .In monitoring treatment, culture 
examinations are merely confirmatory. It is exceptional for patients receiving treatment 
to be consistently negative on smear yet positive on culture. 
Clinical assessment: 
Clinical assessment of progress is largely subjective. Disappearance of clinical 
symptoms, general well-being, ability to resume normal activities, and weight gain are 
all pointers to clinical progress. Persistence or reappearance of symptoms plus weight 
loss – i.e. objective clinical deterioration – indicates the need for further investigations 
by sputum microscopy. Erythrocyte sedimentation rate and other tests are unreliable 
and unnecessary in monitoring progress. Clinical assessment is often the only means 
available for judging progress in extra pulmonary and smear-negative pulmonary 
tuberculosis. Weight gain is a valuable indicator in such cases. 
Assessment by radiography: 
Serial radiography is still preferred by many physicians. However, several studies have 
demonstrated that this can be very misleading for assessing the progress and eventual 
outcome of treatment. Patients may show radiographic improvement yet still discharge 
tubercle bacilli. Bacteriologically quiescent disease may be classified as treatment 
failure because of residual lesions on the X-ray, including cavitation. Patients with 
persisting bacteriological negativity could show radiographic changes that would be 
interpreted as deterioration by expert assessors. In a study of 112 patients with 
bacteriologically quiescent disease, followed up by bacteriology and radiography for 4 
years, radiographic changes in 35 patients (31%) were classified as deterioration. In 12 
patients (11%), an increase in cavitation or appearance of cavitation was recorded. 
Clearly, assessment by radiographic changes alone can be very misleading 40. 
To summarize microscopic examination of the sputum smear is a reliable and 
inexpensive method for assessing the results of treatment in initially smear-positive 
patients. Radiographic and clinical evaluations are unsatisfactory for assessing 
progress. Smear microscopy is also a valuable guide to progress and outcome: 
Examination of smear-positive patients at 2 months, 5 months, and at the end of 
treatment will give a good indication of the success of treatment in large-scale 
treatment programmes. Follow-up smears provide reliable information about patient 
progress and programme performance. However, the individual patient benefits from 
bacteriological assessment only if, in the event of treatment failure, another course of 
treatment with an effective regimen can be provided.  
 
 
 
 
 
 
  
 
 
MATERIALS AND METHODS: 
Data collection: 
The study  was  conducted in the Institute of Thoracic Medicine, 
Chennai in the period from July 2005 to February 2006 .The study population is 
selected from three tuberculosis units of Chennai city, namely Pulianthope TU , 
Thanthai periyar TU and Saidapet TU. All the patients who received Category II anti-
tuberculosis treatment in the year 2002 in those tuberculosis units were included for 
study. The indications for Category II were being relapse or treatment after default or 
failure or for other reasons. The details regarding treatment details, sputum status and 
treatment outcome at the end of Category II were collected from the tuberculosis 
register (T.R) available in the respective tuberculosis units. Postal cards were sent to 
the patient’s addresses, requesting them to come to the institute for evaluation. The non 
responders were traced personally with the help of staff available at the concerned TUs 
and were interrogated at their door steps.  
The patients were asked regarding their present symptoms with duration, 
past anti-tuberculosis treatment in a questionnaire. Then their sputum was collected in 
sputum cups and culture bottle. Sputum smear was examined using Ziehl-Neelsen 
method for the presence of acid fast mycobacteria. All the culture specimens were 
collected in a sterile culture bottle containing trisodium citrate. The specimens were 
processed with sodium hydroxide ( for decontamination) and then centrifuged. The 
inoculum is then inoculated in Lowenstein –Jensen medium. Chest skiagram was taken 
to all  the patients. For those whose culture was positive for M.tuberculosis that 
specimen was sent to culture & sensitivity testing at Tuberculosis Research Centre. 
Ziehl–Neelsen staining 
1. Select a new unscratched slide and label the slide with the Laboratory Serial 
Number. 
2. Spread sputum on the slide using a broomstick. 
3. Allow the slide to air dry for 15–30 minutes. 
4. Fix the slide by passing it over a flame 3–5 times for 3–4 seconds each time. 
5. Pour filtered carbol fuchsin to cover the entire slide. 
6. Gently heat the slide with carbol fuchsin on it until vapours rise. Do not boil. 
7. Leave carbol fuchsin on the slide for 5 minutes. 
8. Gently rinse the slide with tap water until all free carbol fuchsin stain is washed 
away. 
9. Pour 25% sulphuric acid onto the slide. 
10. Let the slide stand for 2–4 minutes. 
11. Rinse gently with tap water. Tilt the slide to drain off the water. 
12. If the slide is still red, reapply sulphuric acid for 1–3 minutes and rinse gently with 
tap water. 
13. Pour 0.1% methylene blue onto the slide. 
14. Leave methylene blue on the slide for 30 seconds. 
15. Rinse gently with tap water. 
16. Allow the slide to dry. 
17. Examine the slide under the microscope using x40 lens to select the suitable area 
and then 
examine under x100 lens using a drop of immersion oil. 
18. Record the results in the Laboratory Form and the Laboratory Register 
appropriately . 
 
 
Examination 
 
Result Grading 
No. of 
 
fields to be 
examined 
 
More than 10 
AFB per oil 
immersion field 
Positive 3 + 20 
1–10 AFB per oil 
immersion field 
Positive 2 + 50 
10–99 AFB per 
100 oil immersion 
fields 
Positive 1 + 100 
1–9 AFB per 100 
oil immersion 
fields 
Scanty 
Record the 
exact number 
200 
No AFB in 100 
oil immersion 
fields 
Negative 0 100 
 
Reports should state  
¾ If the acid- fast bacilli were seen or not. 
¾ If the acid-fast bacilli were seen , state the number of AFB seen 
¾ Since the M.tuberculosis bacilli can not be microscopically distinguished from 
non tuberculous mycobacteria by smear examination, do not report species. A 
positive report should only state that “acid –fast bacilli” were seen. 
¾ State the method by which the smear was examined ( Ziehl-Neelsen or 
fluorescent microscopy) 
 Data analysis: 
 
The data is entered in to the Microsoft Excel Work sheet and it is analysed using SPSS 
software. 
 
 
 
 
 
 
 
 
  
The Definitions of various outcomes is as follows;  
Determination of treatment outcomes 
If the patient Then the treatment outcome is 
Initially smear-positive patient who has 
completed treatment and had negative 
sputum smears, on at least two occasions, 
one of which was at completion of 
treatment. 
 
cured 
Sputum smear-positive case who has 
completed  treatment, with negative 
smears at the end of the initial phase but 
none at the end of treatment. 
Or: Sputum smear-negative TB patient 
who has received a full course of 
treatment and has not become smear-
positive during or at the end of treatment. 
Or: Extra-pulmonary TB patient who has 
received a full course of treatment and 
has not 
become smear-positive during or at the 
end of 
treatment. 
Treatment completed 
 
who died during treatment, regardless of 
cause. 
Died 
 
Smear-positive who is smear-positive at 5 
months or more after starting treatment. 
Also, a patient who was initially smear-
negative but who became smear-positive 
during treatment. 
 
Failure 
 
who, at any time after registration, has 
not taken anti-TB drugs for 2 months or 
more consecutively. 
 
Defaulted 
 
who has been transferred to another 
Tuberculosis Unit/District and his/her 
treatment results are not known. 
 
Transferred out 
 
RESULTS : 
Break up of the total 143 patients who had ATT Category II: 
Total no of patients registered 143 
Died during treatment period 13 
Remaining 130 
Non traceable  27 
Traced 103 
Died in the follow up period 20 
Sputum and chest Skiagram taken 83 
 
 
 
    Age & sex distribution of the 143 patients: 
 
 
Age Female Male Total 
< 25 8 11 19 
25 - 34 8 33 41 
35 - 44 2 40 42 
45 - 54 2 25 27 
55 - 64 1 11 12 
>65 1 1 2 
Total 22 121 143 
 
The above Table shows that more number of males(121) had Category II than 
females(22).            
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Reasons for starting Category II : 
 
 
Female Male Total  
No No No % 
Relapse 17 55 72 50.3 
TRT after default 1 53 54 37.8 
Failure 2 10 12 8.4 
Others 2 3 5 3.5 
Total 22 121 143 100.0 
p < 0.01 (Chi square) 
 
 
 
The above Table shows that Relapse is the most common reason for starting  Category 
II (n=72), next common reason being Treatment After Default(n=54). More 
importantly the defaulters are mostly males. (p< 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome of all the 143 patients registered under Category II: 
 
 
 
 
NUMBERS 
 
% 
Cured: 
 75 52.4 
Completed: 
 7 4.9 
Defaulted: 
 40 28.0 
Failure: 
 6 4.2 
Transferred out: 
 2 1.4 
Died: 
 13 9.1 
total 143 
 
100 
 
 
The above Table shows that 52.4% (n=75) patients were cured     and 
28%9(n=40)  patients defaulted during treatment  .Overall successful treatment 
completion rate was 58%.(cured + completed treatment) 
 
                 
Outcome of Cat II
Cured
53%
Completed
5%
Defaulted
28%Transfered out
1%
Died
9%
Failure
4%
 
 
 
Split up of outcome according to the reason for starting Category II: 
 
 
Reasons for starting Category II 
Relapse 
Treatment after 
default Failure Others Total 
Outcome at 
the end of 
Category II No % No % No % No % No % 
Cured 52 72.2 23 42.6 0 0.0 0 0.0 75 52.4 
Completed 0 0.0 3 5.6 0 0.0 4 80.0 7 4.9 
Defaulted 11 15.3 25 46.3 3 25.0 1 20.0 40 28.0 
Transferred out 1 1.4 1 1.9 0 0.0 0 0.0 2 1.4 
Died 5 6.9 2 3.7 6 50.0 0 0.0 13 9.1 
Failure 3 4.2 0 0.0 3 25.0 0 0.0 6 4.2 
Total 72 100.0 54 100.0 12 100.0 5 100.0 143 100.0 
p < 0.01 (Chi square test) 
 
The above Table shows that 72.2% (n=52)of the patients with relapse had cured at the 
end of Category II .Out of the 40 defaulters, 25 patients were already defaulters during 
Category I and now again defaulted during Category II. Regarding patients who had 
failure in Category I ( N=12) 6 died   during treatment period  3 met with failure in 
Category II .Death rate was  high (50 %) in the failure group 
 
Reasons for default: 
 
Migrated 2 
Alcoholics 19 
Work pattern  14 
Toxicity / new disease 3 
Indifferent attitude 2 
 
The above Table shows that alcoholism is associated with  significant defaultness 
 
 
 
 
 
 
Reasons for non-traceability: 
 
Wrong address 4 
Shifted 16 
Homeless 5 
Not willing 2 
 
 
 
Co morbid conditions: 
 
Diabetes mellitus 5 
Alcoholism 25 
HIV 3 
 
Regarding comorbid conditions 5 had diabetes mellitus and 3 were HIV positives. All 
the three HIV positives were diagnosed only after receiving Category II. 
 
Concordances of sputum smear with sputum culture:  
 
Sputum culture Sputum smear Positive Negative Contaminated 
Negative  0 70 3 
1+ 2 2 0 
2+ 3 0 0 
3+ 3 0 0 
p < 0.01 
 
The above Table shows that 70 smear negative patients were negative by culture also 
and  all the culture positives(n=8) are positive by smear itself.. Only  two patients who 
had positive smear had negative culture. This shows a good concordance between 
sputum and culture. 
 
 
Outcome at the end of Category II  Vs  present culture status: 
 
 
Negative Positive Contamination Total 
 
No No No No 
Cured 54 5 1 60 
Completed 7 0 0 7 
Defaulted 9 2 2 13 
Failure 2 1 0 3 
Total 72 8 3 83 
p = Not significant 
 
Among the 8 persons who are culture positive, five who were previously declared as 
cured, two were  defaulters , one was failure at the end of Category II. 
 
 
Present clinical status of patients Vs culture: 
 
Present Culture status 
 Negative Positive Total 
Asymptomatic 13 2 15 
Insignificant symptoms 57 1 58 
Significant symptoms 5 5 10 
Total 75 8 83 
             p < 0.001 
 
( Insignificant symptoms = patients with cough,sputum,dyspnoea and 
constitutional symptoms for less than 3 weeks) 
(significant symptoms = patients with cough,sputum,dyspnoea and 
constitutional symptoms for more than 3 weeks)  
 
Outcome at the end of Category II  Vs  present clinical status: 
 
 Asymptomatic Insignificantsymptoms 
Significant 
symptoms 
Died (during 
trt/follow up) 
Non-
traceable 
Cured 11 43 6 8 7 
Completed 2 4 1 0 0 
Defaulted 2 9 2 10 17 
Failure 0 2 1 2 1 
Transferredout 0 0 0 0 2 
Total  15 58 10 20 27 
 
Regarding the clinical status of patients, majority of the patients have insignificant 
symptoms(N=58). There is good association (50%) between patients with significant 
symptoms and culture positivity.  More  importantly, 10 out      of the 40 defaulters died 
(25%). On enquiring the cause for death of  the defaulters , it was found mostly due to 
tuberculosis. 
 
 
Present chest skiagram: 
 
  
Present Smear 
Radiologic feature Negative Positive Total 
Thinwalled cavity 8 0 8 
Thick walled cavity 0 2 2 
Fluffy nodular shadows 0 3 3 
Pleural thickening 8 0 8 
Fibrosis 28 0 28 
Multiple patterns 3 4 7 
Calcification 15 0 15 
Normal 7 0 7 
Total 69 9 78 
. 
Outcome at the end of Category II  Vs  present radiological status: 
 
 
Thin 
walled 
cavity 
Thick 
walled 
cavity 
Fluffy 
nodular 
shadows 
Pleural 
thickening 
Parenchymal 
fibrosis 
Multiple 
patterns Calcification  Normal 
Not 
available 
Cured 6 1 3 7 19 3 13 5 18 
Completed 0 0 0 1 3 1 0 2 0 
Defaulted 2 1 0 0 5 1 0 0 29 
Failure 0 0 0 0 1 2 2 0 3 
T.O 0 0 0 0 0 0 0 0 2 
Total  8 2 3 8 28 7 15 7 52 
 
Chest skiagrams of patients with positive culture showed radiologic patterns like thick 
walled cavity and fluffy nodular shadows . Parenchymal  fibrosis was the predominant 
radiological finding.  
 
 
 
 
Sensitivity pattern of culture positives: 
 
 INH RIF ETHAM STREPTO ETIHO KANA CIPRO 
1 R S S S S S S 
2 R S S S S S S 
3 R R S S S S S 
4 R S S S S S S 
5 R R R S R S S 
6 S S S S S S S 
7 S S S S S S S 
8 S S S S S S S 
R = Resistant      S = Sensitive  
 
From the above table we find that three patients are sensitive to all the 
first line antituberculous drugs ; three patients are resistant to INH alone; one 
patient is resistant to both INH and rifampicin; one patient showed resistance to 
INH ,rifampicin and ethambutol. 
Age wise distribution of died patients: 
 
 Age Total 
 < 25 25 - 34 35 - 44 45 - 54 55 - 64 >65 
Died during follow 
up 3 6 4 6 1 0 20 
Died during 
treatment 1 3 4 2 3 0 13 
Total 4 9 8 8 4 0 33 
 
 
This table shows that age has not affected the death rate. 
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Sex distribution of died patients: 
 
 
Sex 
 Female Male Total 
Died during follow up 4 16 20 
Died during treatment 0 13 13 
Total 4 29 33 
 
This table shows that majority of deaths have occurred in males.  
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DISCUSSION: 
 
 
Totally 143 patients were registered for Category II in the three 
tuberculosis units in the year 2002. Out of the 143 patients, 13 patients died during the 
treatment period itself.  We could not able to trace 27 patients. Finally 103 patients 
were traced. Out of them 20 patients died in the follow up period. 83 patients were 
subjected for sputum examination (smear & culture) and chest skiagram. 
 Relapse is the most common reason for starting  Category II (72 
patients 50%), next common reason being Treatment After Default. Twelve patients 
were started with Category II for failure in Category I.                        
When analysing the outcome at the end of Category II , 75 patients were 
cured       ( cure rate was 53%); 40 patients defaulted during treatment; 4 patients had 
failure with Category  II. Overall successful treatment completion rate was 58%                      
(cured + completed). Out of the 40 defaulters, 25 patients (46.3 %) were already 
defaulters during Category I and now again defaulted during Category II. Regarding 
patients who had failure in Category I ( N=12) 6 died   during treatment period  3 met 
with failure in Category II .Death rate was  high (50 %) in the failure group.  
 
 
In our study 72.2% (n=52)of the patients with relapse had cured at the 
end of Category II. This proves the point that most of the relapses will have drug 
susceptible organisms. According to T. Santha  et al 29 the patients who have relapsed 
can achieve more than 80–90% cure if treated for 8–9 months with five drugs, 
including rifampicin, during the intensive phase and three drugs in the continuation 
phase, since more than 80% of the relapses occur with drug-susceptible organisms 30 
 
This Table compares the outcomes of our study with outcomes of the Indian figures 
projected in the Research dissemination workshop conducted at Chennai in the January 
2005.   
  
Research dissemination 
workshop 
Chennai  
2005 41 
(%) 
 
Our 
Study     
(%)            
Cured 67.2 52.4 
Completed 3.6 4.9 
Defaulted 15.2 28 
Failed 5.8 4.2 
Died 7.5  9.1
Transferred out 0.6 1.4 
 
Cure rate in our study is low as it is significantly influenced by high 
defaulter rate in our study (28% ) than the results of research dissemination workshop 
which was conducted in Chennai in the year 2005 by Dr. Fraser from WHO  
(15.2%)41. 
 
In a similar study by  Sophia Vijay, V.H. Balasangameshwara et al18 
the overall favorable treatment outcome was 39.8% (cure 33.6%), treatment completion 
rate (6.2%) with 43.8% of patients having defaulted from treatment. 
 When looking at the various reasons for defaultness, alcoholism was the 
main reason.  The next common reason was the work pattern. Persons with wandering 
jobs like drivers, businessmen, merchants and daily laborers   had poor compliance 
during  treatment. 
Under the operational conditions, it has been observed that less than 3% of 
new cases fail to the Category I treatment regimen and 6%( our study 5.8%) fail 
amongst the retreatment patients treated with the RNTCP Category II regimen. It is 
being realized that, as DOTS programmes around the world become robust enough to 
manage the majority of patients who carry drug-sensitive strains, efforts should begin 
to provide better services for the minority of patients with MDR-TB14-15 
 
In study by Sophia et al18the overall high proportion of ‘default’( 43.8% 
Vs 28% of our study) in the study group had considerably affected the expected 
favorable outcome, which represents failure to keep patients on DOTS, rather than 
ineffectiveness of Category II regimen 
In a study by Sophia et al38 those predicted at risk of default with DOT 
in a metropolitan setting are most likely to be males, alcoholics, and those missing one 
or more doses in IP particularly after twelfth dose. In addition, re-treatment patients 
belonging to the type TAD and having poor knowledge of disease are also likely to 
default. 
 
Among the 83 patients traced , 8 are positive by culture (10%). Among 
the 8 persons five who were previously declared as cured at the end of Category II, two 
were defaulters , one was failure. The reasons for the previously cured patients 
becoming culture positive may be due to relapse or reinfection. Only one patient from 
the failure group became culture positive. But , since the number of failure patients in 
the study population is low and six of them already died, we can not draw any 
significant conclusion from this point.  
Regarding the need for regular follow up , The highest relapse rate is 
found in patients who have never received any treatment (about 5% per annum) and the 
next highest rate (about 2%) in patients with prior inadequate treatment 34After 3–5 
years, the risk of relapse in both groups diminishes appreciably, to about 1% 34 . In 
patients who have been adequately treated, the risk of relapse is too small to justify 
prolonged follow-up 35. Thus, routine follow-up examinations are generally 
unnecessary. This conclusion was reached by the Centers for Disease Control of the 
Public Health Service in the USA 36, as well as by investigators who followed up 
patients treated in Scotland . The former stated 36 “Tuberculosis patients who complete 
adequate chemotherapy should be considered cured. They have no need for routine 
lifetime periodic recall for X-ray examination. Indeed, perpetuating life-time follow-up 
of such treated patients diverts clinic personnel and resources from the crucial task of 
providing services for those who really need them.” However, ex-patients should be 
strongly advised to come for examination without delay if they develop symptoms 
suggestive of tuberculosis 35. General practitioners and physicians who are likely to 
encounter patients with a history of previous tuberculosis should be informed about the 
possibility of relapse and the need to promptly evaluate recurrent respiratory symptoms 
(such as prolonged cough). 
 
Regarding the culture and sensitivity , three patients are sensitive to all 
the first line antituberculous drugs ; three patients are resistant to INH alone; one 
patient is resistant to both INH and rifampicin; one patient showed resistance to INH 
,rifampicin and ethambutol. Interestingly that patient failed in both Category I and II. 
So among the 83 patients subjected for the culture examination 8 are positive(10%); 
two patients are  having multi-drug resistant tuberculosis. 
According to T. Santha  et al 29 more than 80% of the relapses occur with drug-
susceptible organisms 30. 
 
 Tuberculosis research centre Chennai in a controlled clinical trial of 
using standardized short-course regimens for treating newly  diagnosed sputum smear 
positive (NSS) patients, 81% of 320 patients with H resistance, had favourable 
treatment outcome and 13% had bacteriological relapse, respectively, during a 24-
month period of follow up. Thus, 18 patients with resistance to H at  the time of failure 
also are likely to respond to treatment with Cat II regimen. Another 27% were negative 
by culture and there is no cause for concern in treating these patients with Category II 
regimen.  
In study by Sophia et al18, Despite previous TB treatment, 60% of the 
study cohort was pre-treatment susceptible to all the four drugs despite the prevailing 
concept that a  majority of the re-treatment cases have acquired drug resistance and 
may not respond to Category II regimen. Treatment adherence is crucial for the success 
of chemotherapy. The overall emergence of resistance to Rifampicin during treatment 
under direct observation was negligible (1.8%), despite a high default rate. This further 
supports the robustness of the category II regimen given under direct observation, in 
preventing the emergence of drug resistance during treatment. 
Failures to Category I treatment regimen may not always have MDR-TB, particularly if 
the entire treatment was not directly observed26. 
A programme-based study from Malawi by Harries AD, Nyierenda 
TE, Kemp JR, et al, of the 90 patients who failed treatment, 31 (34%) had sputum 
specimens sent either to the Central Research Laboratory. Of these, 11 specimens grew 
organisms resembling M. tuberculosis. Of the remainder, two specimens grew 
organisms that were not M. tuberculosis, 15 were culture-negative and three were 
contaminated. Of the 11 cultures with M. tuberculosis, eight showed full sensitivity to 
all drugs tested, while three showed mono-resistance to isoniazid and full sensitivity to 
the other drugs. This study confirms that the Malawi NTP policy of  offering a standard 
WHO retreatment regimen to failure cases is entirely appropriate. 
  
In analyzing deaths, it was found that more number of males died than 
females; death rate is not influenced by age . On enquiry more number of deaths were 
due to tuberculosis. 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS: 
 
The purpose of the present study is to address the often-posed query regarding 
effectiveness of Category II regimen for re-treatment. 
In Our study the cure rate is 53% and overall successful treatment completion rate is 
58%. Since that was the early days of implementation of the programme and the 
number of staff exclusively available were less, the outcome of  the patients who had 
Category II is acceptable . 
 46.3 % of Category I defaulters again defaulted in Category II. Recommendations to 
be formulated concerning management of TB patients with respect to the risk of 
treatment default. 
In the three year follow up it is found that five of the cured patients of Category II now 
found to be positive by culture. This stresses the importance of prompt evaluation of 
patients who have completed the treatment in the presence of recurrent chest 
symptoms. 
Out of the 83 patients subjected for culture examination, only five patients showed drug 
resistance and among the five patients only two were having multi drug resistant 
tuberculosis. With this low incidence of drug resistance , Category II will be adequate 
under programme conditions for the management of re-treatment cases. 
 
 
 
  
SHORT COMINGS OF THE STUDY: 
¾ We are not able to trace about 27 patients. 
¾ We are not able to trace many of the defaulters 
¾ The number of patients in failure Category is less 
¾ Pretreatment chest skiagrams and culture sensitivity was not available 
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ABBREVIATIONS: 
 
CTD  Central Tuberculosis Division  
DOTS  Directly Observed Therapy Short course 
DMC  Disignated Microscopy Centre  
EPTB  Extra Pulmonary Tuberculosis 
INH  Isonicotinic acid Hydrazide  
MDR-TB Multi Drug Resistant Tuberculosis 
NSS  New sputum  Smear  positives      
PAS  Para Amino Salicylic acid 
PHI  Peripheral Health Institution  
PTB  Pulmonary Tuberculosis 
RNTCP Revised National Tuberculosis Control Programme 
TU  Tuberculosis Unit 
TAD  Treatment After Default 
WHO  World Health Organisation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
S.NO AGE SEX REASONS COMPLIANCE OUTCOME COMORBID CONDITIONS 
PRESENT 
SMEAR 
PRESENT 
CULTURE 
CLINICAL 
STATUS 
CHEST 
SKIAGR
1 23 1 1 1 1 0 0 0 2 5 
2 25 1 1 1 1 0 4 4 6 9 
3 32 1 1 1 1 0 0 0 2 4 
4 21 1 1 1 1 0 0 0 2 1 
5 36 1 1 2 3 2 4 4 6 9 
6 56 0 1 1 1 1 1 1 3 6 
7 21 1 1 5 5 0 4 4 5 9 
8 35 1 1 1 1 2 2 1 3 3 
9 27 0 3 1 6 0 4 4 4 9 
10 25 1 4 1 3 0 4 4 6 9 
11 36 1 3 1 5 0 4 4 5 9 
12 43 1 3 1 5 0 4 4 5 9 
13 30 1 1 1 1 0 0 0 2 9 
14 24 1 2 2 3 0 4 4 4 9 
15 38 1 1 1 1 0 4 4 4 9 
16 48 1 1 1 1 0 4 4 4 9 
17 32 1 1 4 5 0 4 4 5 9 
18 33 1 3 3 3 2 0 2 2 1 
19 38 1 2 2 3 2 3 1 2 2 
20 44 1 2 1 1 1 0 0 1 1 
21 52 1 2 1 1 0 0 0 2 5 
22 50 1 1 1 1 2 1 0 3 3 
23 55 1 1 3 3 0 4 4 6 9 
24 57 1 1 5 5 0 4 4 5 9 
25 35 0 1 1 1 0 0 0 2 5 
26 42 1 2 3 3 2 4 4 4 9 
27 18 0 1 1 1 0 0 0 2 8 
28 68 1 2 2 3 0 4 4 6 9 
29 58 1 2 2 3 2 4 4 6 9 
30 22 0 4 1 2 0 0 0 2 8 
31 38 1 3 2 5 0 4 4 5 9 
32 34 1 3 2 3 2 2 1 3 9 
33 40 1 1 1 1 0 0 0 2 7 
34 65 1 2 3 3 2 4 4 6 9 
35 28 1 4 2 2 0 0 0 1 8 
36 53 1 1 2 3 0 4 4 4 9 
37 26 0 3 1 6 0 3 1 3 6 
38 21 0 1 3 4 0 4 4 6 9 
39 46 1 1 1 1 0 0 0 2 5 
40 65 1 1 1 1 0 4 4 6 9 
41 43 1 1 1 1 0 4 4 6 9 
42 35 1 1 1 1 0 0 0 2 1 
43 40 1 2 2 3 2 4 4 6 9 
44 52 1 2 1 1 0 0 0 2 4 
45 22 1 2 2 3 0 4 4 4 9 
46 38 1 2 3 2 0 0 0 2 5 
47 36 1 2 5 5 0 4 4 5 9 
48 62 1 4 1 2 0 0 0 1 4 
49 48 1 1 1 1 0 0 0 2 7 
50 26 1 3 2 3 0 4 4 4 9 
51 42 1 1 1 1 1 0 0 1 5 
52 30 1 1 1 1 0 2 1 1 6 
53 51 1 2 1 1 0 0 0 2 7 
54 60 1 3 4 5 0 4 4 5 9 
55 60 1 1 1 1 0 4 4 4 9 
56 40 1 1 1 1 0 0 0 2 5 
57 40 1 2 3 3 0 4 4 6 9 
58 35 0 1 1 1 0 0 0 2 5 
59 55 1 1 1 1 0 4 4 4 9 
60 45 1 2 2 3 0 0 0 2 5 
61 45 1 2 2 4 0 4 4 6 9 
62 47 0 2 1 2 0 0 0 2 5 
63 48 1 1 1 1 0 4 4 4 9 
64 25 0 1 1 1 0 4 4 4 9 
65 21 0 1 1 1 0 0 0 1 5 
66 42 1 1 1 1 0 0 2 2 4 
67 40 0 4 1 2 0 0 0 2 5 
68 17 0 1 3 6 0 4 4 6 9 
69 50 1 3 5 5 0 4 4 5 9 
70 35 1 2 1 1 0 0 0 2 9 
71 45 1 2 1 1 0 0 0 1 4 
72 33 1 3 5 5 0 4 4 5 9 
73 43 1 3 2 6 3 0 0 2 6 
74 50 1 1 1 1 0 0 0 2 5 
75 29 0 1 1 6 0 4 4 4 9 
76 53 1 2 4 5 0 4 4 5 9 
77 34 1 1 1 1 0 4 4 6 9 
78 28 1 1 1 1 0 0 0 2 7 
79 45 1 1 1 1 0 0 0 2 7 
80 30 1 1 1 1 0 0 0 2 8 
81 59 1 1 5 5 0 4 4 5 9 
82 46 1 1 1 1 0 4 4 4 9 
83 45 1 1 1 1 0 0 0 2 5 
84 30 1 1 2 3 0 4 4 6 9 
85 37 1 1 1 1 0 0 0 2 4 
86 17 0 1 1 1 0 0 0 1 8 
87 38 1 1 3 3 2 0 0 1 5 
88 45 1 1 2 3 0 4 4 6 9 
89 33 1 1 5 5 0 4 4 5 9 
90 28 1 1 3 3 0 4 4 6 9 
91 55 1 2 2 3 0 4 4 4 9 
92 45 1 2 1 1 0 4 4 4 9 
93 50 1 1 1 1 0 0 0 2 5 
94 59 1 2 1 1 0 0 0 2 4 
95 26 0 1 2 3 0 4 4 4 9 
96 55 1 1 1 1 0 0 0 3 1 
97 46 1 2 1 1 0 0 0 2 7 
98 44 1 2 2 3 2 0 2 3 6 
99 46 0 1 1 1 0 0 0 2 7 
100 27 1 2 1 1 0 0 0 2 7 
101 42 1 2 1 1 2 1 1 3 2 
102 41 1 1 1 1 2 0 0 2 5 
103 57 1 1 1 1 0 4 4 6 9 
104 16 0 1 1 6 0 0 0 2 5 
105 38 0 1 1 1 0 0 0 2 1 
106 30 1 2 2 3 2 0 0 1 7 
107 48 1 1 2 3 2 4 4 6 9 
108 34 1 2 2 3 0 4 4 4 9 
109 48 1 2 1 1 0 0 0 1 8 
110 27 1 2 2 3 3 4 4 6 9 
111 35 1 2 1 1 0 3 1 1 3 
112 45 1 2 1 1 0 4 4 6 9 
113 42 1 2 2 3 2 0 0 2 9 
114 45 1 2 1 3 0 0 0 2 5 
115 24 1 1 1 1 0 0 0 1 7 
116 27 1 2 1 1 0 0 0 1 7 
117 56 1 2 2 3 3 0 0 2 1 
118 30 1 2 2 3 2 0 0 2 7 
119 25 1 2 1 1 0 0 0 2 5 
120 41 1 2 1 1 0 0 0 2 5 
121 35 0 1 1 1 0 0 0 2 5 
122 40 1 1 1 1 0 0 0 2 5 
123 43 1 2 1 1 2 1 0 3 6 
124 36 1 2 3 3 0 4 4 4 9 
125 23 1 1 1 1 0 0 0 2 5 
126 33 1 2 1 1 0 0 0 2 1 
127 27 1 2 1 2 0 0 0 3 6 
128 35 1 2 2 3 2 0 0 2 5 
129 37 1 2 2 3 2 4 4 6 9 
130 45 1 2 1 1 1 0 0 2 7 
131 52 1 1 1 1 0 0 0 2 4 
132 26 1 1 1 1 0 4 4 6 9 
133 55 1 2 2 3 0 0 0 2 5 
134 26 1 1 3 3 2 4 4 4 9 
135 35 1 2 1 1 0 0 0 2 7 
136 46 1 1 2 3 0 4 4 6 9 
137 29 1 1 1 1 2 0 0 2 9 
138 30 0 1 1 1 0 0 0 1 7 
139 33 1 2 2 3 2 4 4 6 9 
140 52 1 2 1 1 1 0 0 2 5 
141 21 1 2 1 1 0 0 0 2 5 
142 45 1 2 2 3 2 4 4 6 9 
143 66 0 1 1 1 0 0 0 2 8 
 
 
KEY TO MASTER CHART: 
 
 
SEX: 
MALE         1 
FEMALE    0 
 
 
 
REASONS FOR CATEGORY II: 
RELAPSE     1     
TREATMENT AFTER DEFAULT   2       
FAILURE     3                   
OTHERS     4       
 
 
 
COMPLIANCE: 
REGULAR TREATMENT        1 
DEFAULTED IN I P                   2 
DEFAULTED IN C P                  3 
DIED IN   1   P                             4   
DIED IN   C   P                            4   
 
 
 
OUTCOME AT THE END OF CATEGORY II: 
CURED   1 
COMPLETED  2 
DEFAULTED  3  
TRANSFERRED OUT 4 
DIED    5  
FAILURE   6 
 
 
COMORBID ILLNESS: 
 DIABETIC  1 
 ALCHOHOLISM 2 
 HIV   3 
 NIL   0 
 
 
 
 
 
 
PRESENT SPUTUM  SMEAR: 
 NEGATIVE  0 
 ONE PLUS  1  
 TWO PLUS  2 
 THREE PLUS 3 
 NOT DONE  4   
 
 
PRESENT SPUTUM CULTURE: 
 NEGATIVE   0 
 POSITIVE   1 
 CONTAMINATED  2 
 NOT DONE   4 
  
 
PRESENT CLINICAL STATUS: 
 ASYMTOMATIC   1 
 INSIGNIFICANT SYMPTOMS 2 
 SIGNIFICANT SYMPTOMS 3 
 DIED DURING FOLLOW UP 4 
 DIED DURING TREATMENT 5 
 NOT TRACEABLE   6 
 
PRESENT  CHEST SKIAGRAM: 
 THIN WALLED CAVITY  1  
 THICK WALLED CAVITY 2 
 FLUFFY NODULAR SHADOWS 3 
 CALCIFIC NODULES  4  
 PARENCHYMAL FIBROSIS 5 
 MULTIPLE PATTERNS  6  
 PLEURAL THICKENING  7 
 NORMAL    8 
 NOT TAKEN   9 
 
 
 
